Related Experiment Video
Updated: Jun 15, 2026

Characterizing Modulators of Protease-Activated Receptors with a Calcium Mobilization Assay Using a Plate Reader
Published on: May 24, 2024
Paraoxonase 1 attenuates human plaque atherogenicity: relevance to the enzyme lactonase activity
Hagai Tavori1, Jacob Vaya, Michael Aviram
1The Lipid Research Laboratory, Technion Faculty of Medicine, Rappaport Family Institute for Research in the Medical Science and Rambam Medical Center, 31096, Haifa, Israel. hagait@migal.org.il
Abstract:
Human atherosclerotic lesions contain a variety of lipids and oxidized lipids, which can induce atherogenic properties such as macrophage oxidation, lipoprotein oxidation and inhibition of cholesterol efflux from macrophages. These atherogenic properties of the plaque's lipid fraction are associated with the inhibition of paraoxonase 1 (PON1) lactonase activity. In contrast, incubation of PON1 with the plaque's lipid fraction reduces the lesion's atherogenic properties by lowering the capacity of the oxidized lipids to induce further oxidation. The mechanism of PON1's protective action and its endogenous substrate however remain elusive. Modeling studies may characterize PON1's possible active site, and help envisage the structure of potential endogenous and exogenous lactones as PON1 ligands. Such modeling thus may lead to a better understanding of PON1's anti-atherogenic mechanism of action.
Related Concept Videos
Indirect-Acting Cholinergic Agonists: Mechanism of Action
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex, leading to...
Atherosclerosis I: Introduction
Pharmacogenomics: Identification of New Drug Targets
Allosteric Proteins-ATCase
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis pathway,...
Adrenergic Receptors: ɑ Subtype
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase C—inositol-1,4,5-trisphosphate...
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
